Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 DAYBREAK open-label extension (OLE) study in relapsing multiple sclerosis. For participants who showed no evidence of recent COVID-19 infection, results showed seroconversion occurred in 100% (80/80) and 62% (18/29) of fully vaccinated mRNA and non-mRNA vaccine recipients, respectively. These data are to

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)

British American Tobacco

FedEx

These stocks offer dividend yields ranging from 2% to an astronomical 7.1%.

3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist

The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.

Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Bcell--European Medicines Agency Validates BMS's Application for CAR T Cell Therapy Breyanzi....

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy

AbbVie

Royalty Pharma

Verizon

Wells Fargo

One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.

5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. Bhatt will serve as a member of the Science & Technology Committee of the Board of Directors. “We are pleased to welcome Dr. Deepak L. Bhatt to our Board of Directors,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “Through his role as a physician and leading r

Bristol Myers Squibb Elects Deepak L. Bhatt, M.D.

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 PM ET CorporateParticipants Adam Lenkowsky - Senior Vice President and General Manager, U.S. Commercialization ConferenceCall Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, good morning, everybody. This is the place to be obviously with Pfizer and now with Bristol.

Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

Broadcom

Caterpillar

McDonald's

Altria

Procter & Gamble

Blue-Chip stocks are particularly attractive in volatile times like now. These picks include a strong dividend as well.

7 Blue-Chip Stocks With Strong Dividend Yields

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2022 on Wednesday, July 27, 2022. Company executives will review financial results and address inquiries from investors and analysts during a conference call at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. To be directly connected to the conference call, enter your information here; the link

Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 15, 2022. Adam Lenkowsky, Senior Vice President and General Manager, U.S. Commercialization, will answer questions about the company at 9:20 a.m. PT/12:20 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http

Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

Axcelis Technologies

Arista Networks

Mastercard

Realty Income Corp

Perion Network

Visa

Investors foolishly sent these stocks into cheap territory, ignoring the near-term growth prospects that will reward them soon. The post 7 Cheap Growth Stocks That Won't Stay That Way for Long appeared first on InvestorPlace.

7 Cheap Growth Stocks That Won't Stay That Way for Long

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo Plus Yervoy in First-Line....

Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo Plus Yervoy ....

Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Bristol Myers Squibb stock (NYSE: BMY), which currently trades at $75 per share, looks like it has only a little room for growth.

Is There More Room For Growth In Bristol Myers Squibb Stock?

BioNTech SE

Merck

Moderna

Pfizer

These were the industry's bestsellers last year, but how long can they stay on top?

Can the Best-Selling Drugs of 2021 Repeat Their Performance?

Immatics NV

Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.

BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer

ACADIA Pharma

Axsome Therapeutics

bluebird bio

Rhythm Pharmaceuticals

Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead of These June Catalysts appeared first on InvestorPlace.

6 Biotech Stocks to Buy Now Ahead of These June Catalysts

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® for Non-transfusion Dependent (NTD) Beta Thalassemia

Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia

Turning Point Therapeutics

Wilmington, Delaware--(Newsfile Corp. - June 3, 2022) - Rigrodsky Law, P.A. is investigating Turning Point Therapeutics, Inc. ("Turning Point") (NASDAQ: TPTX) regarding possible breaches of fiduciary duties and other violations of law related to Turning Point's agreement to be acquired by Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the agreement Turning Point's shareholders will receive $76.00 in cash for each share of Turning Point common stock they own.To learn more about this investigation...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Turning Point Therapeutics, Inc. Buyout

Turning Point Therapeutics Inc. ( TPTX , Financial) shareholders got a good start to the weekend as the stock soared on news that Bristol-Myers Squibb Co. ( BMY , Financial) is buying the San Diego-based biopharmaceutical company for $76 a share.

Turning Point Therapeutics' Shares Soar on Bristol-Myers Squibb Deal

NEW YORK , June 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Turning Point Therapeutics, Inc. ("Turning Point" or the "Company") (NASDAQ: TPTX), in connection with the proposed acquisition of the Company by Bristol-Myers Squibb Company (NYSE: BMY) via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $76.00 in cash for each share of Turning Point common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.

Turning Point Therapeutics Inc (NASDAQ: TPTX) jumped 110% after announcing a definitive merger agreement with Bristol Myers Squibb Co (NYSE: BMY). Under the agreement, Bristol Myers Squibb will acquire Turning Point at $76 per share.

Here is Why Turning Point Therapeutics Jumped 110%

Shares of Turning Point Therapeutics Inc (NASDAQ: TPTX) more than doubled on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biotech company for $4.10 billion in cash. Bristol-Myers to pay $76 a share for TPTX The pharmaceutical giant is paying $76 a share for Turning Point that represents a 116% premium […] The post Turning Point Therapeutics shares more than doubled on Friday appeared first on Invezz.

News for Bristol-Myers Stock (BMY)